Roy Decker MD/PhD

Associate Professor of Therapeutic Radiology and Assistant Professor of Surgery (Otolaryngology); Clinical Research Program Leader, Therapeutic Radiology, Yale Cancer Center

Specialties & Subspecialties

Cancer Center, Yale: Head and Neck Cancer Surgery Program | Thoracic Oncology Program

Therapeutic Radiology/Radiation Oncology


Radiation Oncology

Education & Training

  • B.A., University of Virginia (1988)
  • M.D./Ph.D., Medical College of Virginia, Richmond, Virginia (2002)
  • Resident, Yale-New Haven Hospital , Radiation Oncology (2003 - 2007)
  • Intern, Medical College of Virginia Hospital , Internal Medicine

Patient Care

Accepts New Patients? Yes | Patient Type: Adult, Child | Accepts referrals from patients

Clinical Interests

Head & Neck Cancer; Lung Cancer; Stereotactic Body Radiosurgery

Cancers Treated

Brachytherapy, Head & Neck, Lung, Prostate, Stereotactic Radiosurgery

Board Certifications

  • Therapeutic Radiology, Board Certified (2008)

Clinical Trials

ConditionsStudy Title
Head and Neck Cancer, Larynx, and Lip, Oral Cavity and PharynxRTOG 0920: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer {CIRB}
Unknown SitesMolecular Predictors of Radiation Resistance
RTOG 1216: Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck {CIRB}
Brain and Nervous System and Other Respiratory and Intrathoracic OrgansA randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemo-radiotherapy in primary unresected patients with stage III, IVa, or IVb loco-regionally advanced head and neck squamous cell carcinoma
LungLCCC 1123: Phase II Study Of Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib for Patients with EGFR Mutation Who Have Previously Progressed on an EGFR Tyrosine Kinase Inhibitor (TKI)

More Clinical Trials...

Edit Profile